Measuring Clinical Treatment Response in Myasthenia Gravis
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Neurologic Clinics
- Vol. 36 (2) , 339-353
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Comparison of IVIg and PLEX in patients with myasthenia gravisNeurology, 2011
- Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7Neurology, 2010
- The MG CompositeNeurology, 2010
- The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: A clarification of its contentBMC Medical Research Methodology, 2010
- Identification of international classification of functioning, disability and health relevant categories to describe functioning and disability of patients with myasthenia gravisDisability and Rehabilitation, 2009
- IV immunoglobulin in patients with myasthenia gravisNeurology, 2007
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001
- Preliminary Results of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine in Myasthenia GravisNew England Journal of Medicine, 1987
- A methodological framework for assessing health indicesJournal of Chronic Diseases, 1985